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Background: In last years, an increasing interest emerges on the role of sub-lobar resection and lobe-
specific lymph nodal dissection in the treatment of early-stage lung cancer. The aim of our study was to 
define the impact on cumulative incidence of recurrence (CIR) of type of surgical resection and type of nodal 
staging in this subset of patients. Furthermore, we evaluated the possible synergism between the different 
kinds of procedure.
Methods: An analysis of 969 consecutive stage I pulmonary adenocarcinoma patients, operated in six 
Thoracic Surgery Institutions between 2001 and 2013, was conducted. Type of surgical resection included 
lobectomy and sub-lobar resection; while pneumonectomy and bilobectomy were excluded from the analysis. 
Nodal staging procedures were classified in nodal sampling (NS), lobe-specific lymph node dissection 
(LS-ND) and systematic lymph node dissection (SND). Multivariable-adjusted comparisons for CIR was 
performed using Fine and Grey model, taking into account of death by any cause as competing event. In 
order to evaluate synergism between the different procedures, the test of interaction between type of surgical 
resection and type of nodal staging was carried out and results presented in a stratified way. 
Results: Eight-hundred forty-six (87%) patients were submitted to lobectomy, while 123 (13%) to sub-
lobar resection. Four-hundred fifty-five (47%) patients received SND, 98 (10%) LS-ND and 416 (43%) NS. 
Two-hundred forty-seven (26%) patients developed a local/distant recurrence with a 5-year CIR of 24.2%. 
Multivariable-adjusted comparisons showed an independent negative effect of sub-lobar resection (HR 
=1.52; 95% CI: 1.07–2.17), LS-ND (HR =1.74; 95% CI: 1.16–2.6) and NS (HR =1.49; 95% CI: 1.12–1.98) 
on CIR. Test of interaction showed a homogeneity of results among subgroups.
Conclusions: Patients affected by stage I pulmonary adenocarcinoma and submitted to lobectomy 
presented a significant lower recurrence rate than those submitted to sub-lobar resection. Moreover, SND 
presented an independent positive effect on recurrence development than other lymph node assessment 
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Introduction
Non-small cell lung cancer (NSCLC) confirmed to be a 
major public health issue worldwide (1). In this context, 
20% of whole NSCLC were diagnosticated as early stage (2), 
while lung adenocarcinoma accounted 70% of all NSCLC 
cases (3).
Currently, lobectomy with radical lymph node dissection 
represent the standard of care for resectable NSCLC 
(4,5). Nonetheless, in last years, an increasing interest 
emerges on the role of sub-lobar resection in the treatment 
of stage I lung cancer. Undeniably, the possibility to 
perform parenchymal sparing resection (i.e., anatomical 
segmentectomy and wedge resection), primarily reserved 
to unfit patients, to the whole cases of early stage NSCLC 
fascinated numerous surgical groups over the years. 
However, the only randomized clinical trial comparing 
sub-lobar resection with lobectomy for clinical stage IA 
NSCLC demonstrated an inferior survival and a higher 
local recurrence rate in the limited resection group (5). Still, 
interest concerning convenience of limited lung resections in 
early stage NSCLC remains and numerous studies could be 
found in recent literature, assessing their equivalence with 
lobectomy in term of survival and recurrence rate (6-11).
On the other hand, lymph nodal status is one of the 
most important prognostic factors in the management of 
NSCLC (12). However, optimal lymph node assessment 
strategy is still  matter of debate amongst surgical 
community. Indubitably, systematic nodal dissection (13), 
in respect of lymph nodal sampling (NS), provides 
a more accurate pathological staging and allows to 
sterilize unknown or microscopic neoplastic lymph node 
spreading (14). Nevertheless, new minimally invasive biopsy 
techniques (15,16) and high definition imaging rise doubts 
on unavoidability of such aggressive nodal assessment. 
Accordingly, the aim of our study was to define impact 
on Cumulative incidence of recurrence (CIR) of type of 
surgical resection and type of nodal staging. Furthermore, 
we evaluated the possible synergism between the different 
kinds of procedure.
Methods 
From 2001 to 2013, patients who underwent lung surgical 
resection with curative intent for stage I pulmonary 
adenocarcinoma in six thoracic surgery institutions 
(Appendix A) were retrospectively reviewed.
Extended resection (i.e., combined lung and chest wall/
diaphragm resections), pneumonectomy, bilobectomy 
or preoperative treatment regimen (e.g., chemotherapy, 
radiotherapy) represented the exclusion criteria from this 
study.
The preoperative assessment of patient encompassed 
chest radiographs; thoracic-, brain- and upper-abdominal 
computed tomography (CT) scans or whole-body 
18-fluorodeoxyglucose positron emission tomography (PET), 
or both; fiber-optic bronchoscopy; electrocardiograms and 
lung function tests.
Surgical procedures were performed either through 
thoracotomy (muscle-sparing axillary or posterolateral) or 
video-assisted thoracic surgery (VATS).
Data variables and outcomes
The final data set for the analyses included the following 
data: age, gender, smoking habit, side of intervention, type 
of surgical resection, type of intraoperative lymph node 
assessment, pathological TNM (pTNM) stage (according 
to 7th edition), vascular invasion, predominant histologic 
pattern and histologic grade and survival data. 
Type of surgical resection were divided into lobectomy 
and sub-lobar resection (encompassed wedge and segmental 
resection). 
Lymph node station were classified according to IASLC 
8th edition lymph node map (12). Type of intraoperative 
lymph node assessment was classified as follow: (I) lymph 
NS consisted in the removal of one or more lymph nodes, 
guided by preoperative or intraoperative findings; (II) lobe-
specific lymph node dissection (LS-ND), encompassed 
the resection of only stations which are considered as 
the natural drain for that lobe (Appendix B) (17,18); (III) 
strategy. Finally, lobectomy in combination with systematic lymph nodal resection showed the best results in 
term of CIR.
Keywords: Non-small cell lung cancer (NSCLC); lobectomy; lymphadenectomy; staging
Submitted May 03, 2018. Accepted for publication Jan 09, 2019.
doi: 10.21037/jtd.2019.01.31
View this article at: http://dx.doi.org/10.21037/jtd.2019.01.31
566
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2019;11(2):564-572jtd.amegroups.com
Guerrera et al. Risk of recurrence in stage I adenocarcinoma
systematic nodal dissection (SND), in which, according to 
ESTS (13), all mediastinal tissue containing lymph nodes 
is dissected and removed systematically within anatomical 
landmarks; the hilar and the intrapulmonary lymph nodes 
are dissected as well, and at least three mediastinal nodes 
are excised as a minimum requirement.
Surgery was defined as radical (R0) when a complete 
tumor resection was accomplished, and incomplete in case 
of microscopically (R1) or macroscopically (R2) residual 
disease.
Histological grading was categorized into well- (G1), 
moderately- (G2) and poorly differentiated (G3) carcinoma 
according to degree of architecture and cytological atypia.
The adenocarcinoma predominant patterns were 
determinate according to the criteria of the International 
Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society (IASLC/
ATS/ERS) (19). The following predominant patterns 
were clustered in the “Common Variants” group in order 
to simplify the analysis: Solid, Micropapillary, Acinar and 
Papillary. 
The study was approved by the IRB of each participating 
center. 
Statistical analysis
Categorical data are presented as number (percentage, %), 
continuous data as median [interquartile range (IQR)]. 
Missing data in evaluated predictors were multiple-
imputed and combined estimates were obtained from 5 
imputed data sets. Associations between type of surgery, 
type of intraoperative lymph node assessment and 
clinicopathological characteristics were investigated with the 
use of the χ2 test or Fisher’s exact test, when appropriate (20).
Primary outcome was CIR, calculated from the date of 
intervention to the date of tumor distant or local relapse. 
CIR were estimated using the method proposes by Gooley 
et al. (21), taking into account death by any cause (except 
of cancer related death) as competing event. Differences in 
CIR between groups were investigated with Fine and Grey 
model, taking into account of death by any cause (except 
of cancer related death) as competing event. Univariable 
and Multivariable analysis were carried out. Multivariate 
adjusted analysis considers age, gender, smoking habit, 
side of intervention, pTNM stage, vascular invasion, 
predominant histologic pattern and histologic grade. 
Moreover, we explored a potential synergism (the so 
called “effect modification”) between surgical resection and 
intraoperative lymph node assessment in the determination 
of CIR. This potential synergism was evaluated from a 
statistical point of view by including and testing interaction 
terms between variables related to surgical resection and 
intraoperative lymph node assessment in the Fine & Gray 
model. 
The overall survival (OS) was the secondary outcome and 
was defined as the time from the date of the intervention 
to the date of death by any cause. Survival function was 
estimated by Kaplan-Maier method. 
All statistical analyses were performed using STATA 
(version 14) and R (version 3.1).
Results
According to the selection criteria, 969 patients with stage 
I adenocarcinoma of the lung were included in the final 
dataset (Figure S1). Population demographics and clinical, 
surgical and pathologic characteristics of the cohort were 
showed in Table 1. 
Most of the patients are male (658, 68%) and smokers 
(599, 62%). Pathological stage Ia was more commonly 
observed (641, 66%), while the histological predominant 
pattern consisted of acinar adenocarcinoma (442, 46%), 
followed by the papillary (149, 15%), the solid (147, 15%), 
the lepidic (124, 12.8%) and the micropapillary (25, 3%).
Median follow-up was 63 months. A total of 686 (68%) 
were reported to be alive and 283 (32%) died during the 
follow-up period. Overall, the 5-year survival rate was 
74.5% (95% CI: 71.3–77.3%) (Figure 1).
Clinicopathological variables and type of surgical resection 
Table 1 shows the distribution of clinicopathological 
variables according to the type of surgical resection: 
Eight-hundred forty-six (87%) patients were submitted 
to lobectomy, while 123 (13%) to sub-lobar resection [72 
(58%) segmentectomy, 51 (42%) wedge resection]. 
Patients submitted to lobectomy were predominantly 
younger (P=0.002). No difference between type of surgical 
resection was observed in regard to gender, smoking habit, 
pTNM stage, vascular invasion, predominant histological 
pattern and histological grade.
Clinicopathological variables and type of lymph node 
assessment
Table 1 shows the distribution of clinicopathological 
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variables according to the type of lymph nodal assessment: 
455 (47%) patients received SND, 98 (10%) LS-ND and 
416 (43%) NS.
Patients submitted to SND were predominantly younger 
(P=0.009), non-smoker (P=0.043), with higher pTNM stage 
(P<0.001) and less frequently presented vascular invasion 
(P<0.001). No difference between the types of lymph nodal 
assessment was observed in regard to gender, predominant 
histological pattern and histological grade.
CIR analysis
Nine-hundred thirty-seven pat ients  with stage I 
adenocarcinoma of the lung were included in the analyses 
(Figure S1).
Two-hundred forty-seven (26%) patients developed 
a local/distant recurrence with a 5-year CIR of 24.2% 
(95% CI: 21.3–27.1%) (Figure 2). In univariable analysis, 
lobectomy (20.5% vs. sub-lobar resection 38.1%; 20.5%, vs. 
LS-ND 37.8% vs. NS 24.9%; P=0.014) and SND (P=0.001) 

















Age 969 0.002 0.009
≤70 years 597 [62] 537 [63] 60 [49] 297 [65] 48 [49] 252 [61]
>70 years 372 [38] 309 [37] 63 [51] 158 [35] 50 [51] 164 [39]
Gender 969 0.753 0.426
Female 311 [32] 270 [32] 41 [33] 154 [34] 27 [28] 130 [31]
Male 658 [68] 576 [68] 82 [67] 301 [66] 71 [72] 286 [69]
Smokers 969 0.547 0.043
No 370 [38] 320 [38] 50 [41] 180 [40] 26 [27] 164 [39]
Yes 599 [62] 526 [62] 73 [59] 275 [60] 72 [73] 252 [61]
pTNM stage 969 0.251 <0.001
Ia 641 [66] 554 [65] 87 [71] 271 [60] 71 [72] 299 [72]
Ib 328 [34] 292 [35] 36 [29] 184 [40] 27 [28] 117 [28]
Vascular invasion 815 0.08 <0.001
No 643 [79] 567 [80] 76 [72] 342 [78] 59 [65] 242 [85]
Yes 172 [21] 143 [20] 29 [28] 98 [22] 32 [35] 42 [15]
Histologic predominant pattern 959 0.196 0.127
Lepidic 124 [13] 102 [12] 22 [18] 54 [12] 17 [17] 53 [13]
Common variants 762 [79] 671 [80] 91 [74] 365 [81] 79 [81] 318 [78]
NOS—other variants 73 [8] 63 [8] 10 [8] 34 [8] 2 [2] 37 [9]
Histologic grade 955 0.131 0.542
G1 202 [21] 170 [20] 32 [27] 90 [20] 17 [18] 95 [23]
G2 484 [51] 422 [51] 62 [52] 238 [53] 51 [53] 195 [48]
G3 269 [28] 243 [29] 26 [22] 124 [27] 29 [30] 116 [29]
*, χ2 test or Fisher’s exact test. NS, lymph node sampling; LS-ND, lobe-specific lymph node dissection; SND, systematic nodal dissection.
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were found to have a positive effect on survival (Figure 3). 
Combination of lobectomy plus SND showed the best 
recurrence rate pattern (P=0.01; Figure 4).
Multivariable-adjusted comparisons showed an 
independent negative effect of sub-lobar resection (HR 
=1.52; P=0.02; 95% CI: 1.07–2.17), LS-ND (HR =1.74; 
P=0.007; 95% CI: 1.16–2.6) and NS (HR =1.49; P=0.007; 
95% CI: 1.12–1.98) on CIR. Test of interaction showed a 
homogeneity of results among subgroups (Table 2).
Discussion 
The central point in performing more complex surgery is 
to offer an oncological advantage that balances the possible 
additional risks due to the procedure itself. Accordingly, 
lobectomy and systematic nodal dissection are currently 
the cornerstone in the treatment of surgically resectable 
NSCLC. Nevertheless, in last years, several studies 
questioned the established standard of care, highlighted the 
possibility to perform parenchymal preserving resection 
(6-11) and less aggressive nodal assessment strategy 
(18,22,23) in stage I NSCLC. Indeed, the results presented 
by these papers are variegate and often contradictory. 
Moreover, the influence of the combination between type 
of surgical resection and of nodal assessment was rarely 
explored.
Figure 1 Overall survival. Figure 2 Cumulative incidence of recurrence. 
Figure 3 Cumulative incidence of recurrence. (A) According to type of surgical resection; (B) according to type of lymph node assessment. 
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Figure 4 Cumulative incidence of recurrence according to treatment combination. NS, lymph node sampling; LS-ND, lobe-specific lymph 
node dissection; SND, systematic nodal dissection.
Table 2 Multivariable-adjusted fine and grey model for cumulative incidence of recurrence (N=969)
Multivariable analysis* Hazard ratio (95% CI) P Interaction P value





LS-ND vs. SND 0.007 0.903
Overall 1.74 (1.16–2.6)
Lobectomy 1.66 (1.03–2.69)
Sub-lobar resection 1.58 (0.75–3.32)
NS vs. SND 0.007 0.131
Overall 1.49 (1.12–1.98)
Lobectomy 1.61 (1.18–2.19)
Sub-lobar resection 0.88 (0.43–1.82)
*, take into account of age, gender, smoking habit, side of intervention, pTNM stage, vascular invasion, predominant histologic pattern and 
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The results of our study conducted on a cohort of 969 
stage I adenocarcinoma of the lung suggest that (I) patients 
submitted to lobectomy presented a significant lower 
recurrence rate than those submitted to sub-lobar resection, 
(II) systematic lymph node dissection (SND) presented an 
independent positive effect on recurrence development than 
other lymph node assessment strategy, (III) lobectomy in 
combination with systematic lymph nodal resection showed 
the best results in term of CIR.
The benefit of lobectomy over sub-lobar resection 
was established by the results of the study of the Lung 
Cancer Study Group, that represent the only multicenter 
randomized clinical trial on this subject published so far (5). 
This study, conducted by Ginsberg and Rubinstein, 
demonstrated an increase in overall death rate, cancer 
related death and locoregional recurrence rate in sub-
lobar resection group. Similar results were published by 
various authors (6,9,11,24,25). Still, interest concerning 
convenience of anatomical segmentectomy and wedge 
resection in early stage NSCLC remains; numerous studies 
were conducted, assessing to find sub-group of patients that 
may take advantage from these procedures. As matter of fact, 
several groups described the equivalence in term of clinical 
outcomes of lobectomy and lobectomy performed by VATS 
(26-28). Similarly, a number of papers showed no significant 
difference in survival for tumours ≤2 cm in size (6-11). 
Interestingly, numerous authors reported a significant 
reduction of dissected lymph nodes in the segmentectomy 
group than in the lobectomy group (24,28-30).
Our results  showed an independent significant 
advantage of lobectomy on respect of sub-lobar resection 
in term of recurrence rate. Moreover, this benefit remains 
independently from the type of lymph nodal assessment 
performed. Hopefully, the ongoing multicenter randomized 
studies currently conducted by Cancer and Leukemia 
Group B (CALGB 140503) and Japan Clinical Oncology 
Group (JCOG0802/WJOG4607L) (31-33) will solve this 
issue. Till then, sub-lobar resections, as alternative to 
lobectomy, should be proposed only in selected patients (34).
On the other hand, the IASLC staging project in the 
proposals for the revision of the N Descriptor in the 8th 
Edition of the TNM for Lung Cancer stated that “Nodal 
status is considered to be one of the most reliable indicators 
of the prognosis in patients with lung cancer and thus 
is indispensable in determining the optimal therapeutic 
options” (12). Undoubtable, systematic nodal dissection 
provides a higher accurate pathological staging accuracy, in 
reason to the higher number of lymph nodes resected (35). 
Moreover, systematic nodal dissection could consent the 
therapeutic excision of a minimal or unknown disease 
in mediastinal lymph nodes. However, new minimally 
invasive biopsy techniques (15,16) and high definition 
imaging rise doubts on unavoidability of such aggressive 
nodal assessment. Nevertheless, several studies reported 
an unexpected high occurrence of a node-positive occult 
disease in primary and secondary lung tumors (36-39) 
probably due to microscopic lymph nodal involvement. 
Contrariwise, this happened in less than 4% of cases 
ACOSOG Z0030 trial (23); in this study, systematic 
nodal dissection showed no survival benefit of over nodal 
sampling (NS). However, in this trial, all patients were 
submitted to NS and frozen section with the exclusion 
from the randomization for all patients with positive nodes; 
consequently, study conclusions could influenced be by 
this process. In addition, in recent years, some authors 
proposed a new strategy of nodal assessment, consisting in 
the resection of only stations which are considered as the 
natural drain for that lobe (17,18). Several studies compared 
the oncological results of this strategy with the ones of the 
systematic nodal dissection, mostly showing an equivalence 
in term of survival and recurrence rates. 
Our analysis showed an independent benefit of systematic 
nodal dissection over both NS  and lobe-specific nodal 
dissection. Furthermore, this benefit persists independently 
from the type of surgical resection performed. Accordingly, 
a recent metanalysis encompassed more than 1,900 patients, 
reported an improved OS in systematic nodal dissection 
group than in NS group (18). 
Our study presents some limitations. First,  the 
retrospective nature of the analysis relatively limits the 
strength of the results, and this should be considered by 
the readers when conferring clinical value to the reported 
evidence. Moreover, data collection from different centers 
represents an additional significant limitation; indeed, 
despite the centers do not substantially differ in the 
strategy of care adopted in current clinical practice, a series 
of confounding variables are unavoidable, and this bias 
potentially limiting the impact of our results. Concerning 
the type of surgical resection, we encompassed wedge and 
segmental resection as “sub-lobar resection”. On one hand 
this represents a statistical simplification and divers Authors 
have recently reported different recurrence rates between 
the two procedures; on the other hand, considering that 
lobectomy is still the gold standard even in node-negative 
NSCLC measuring less than 3 cm, the distinction between 
lobar and sub-lobar resection has a certain validity although 
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it involves a consistent degree of approximation.
Conclusions
In the present series, lobectomy and SND confirmed to 
be the optimal strategy to achieve a favorable prognosis in 
stage I adenocarcinoma of the lung. The real value of sub-
lobar resection and less aggressive nodal staging should be 
assessed by ongoing randomized clinical trial before being 
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Figure S1 Study flow diagram of the patient population.
975 patients surgical treated for … 
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analysis
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Appendix B
Lobe-specific lymph node dissection encompassed the follow 
lymph node station according to IASCLC lymph node 
map (12): 
- Right upper lobar tumour: Stations 2, 4R and 7;
- Left upper lobar tumour: Stations 5, 6 and 7;
- Right and left middle or lower lobar tumour: Stations 7 
and 9.
